HitGen Inc. entered into a research collaboration agreement with DAEWOONG PHARMACEUTICAL Co. Ltd. HitGen will apply its DNA-encoded library (DEL) technology platform centered around the design, synthesis and screening of thousands of DELs that collectively comprise over 1.2 trillion small, drug-like molecules to discover compounds that bind to certain targets that Daewoong needs to discover for new drug development.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
12.64 CNY | +2.27% | +3.44% | -15.68% |
Apr. 24 | HitGen Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Feb. 23 | HitGen Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-15.68% | 697M | |
+11.60% | 106B | |
-4.68% | 24.28B | |
-0.26% | 21.96B | |
-8.24% | 18.16B | |
-42.12% | 16.37B | |
-17.47% | 15.56B | |
+2.77% | 13.63B | |
+34.58% | 12.27B | |
+77.64% | 8.87B |
- Stock Market
- Equities
- 688222 Stock
- News HitGen Inc.
- DAEWOONG PHARMACEUTICAL Co., Ltd and HitGen Inc. Announces Research Collaboration Focused on DNA-Encoded Library Based Drug Discovery